Dissecting Isoform Selectivity of PI3 Kinase Inhibitors. Uncovering leads for rational drug design.

剖析 PI3 激酶抑制剂的异构体选择性。

• 批准号: nhmrc : 545943
• 负责人: Dr Ian Jennings
• 金额: $ 34.61万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2009
• 资助国家: 澳大利亚
• 起止时间: 2009-01-01 至 2012-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/dissecting-isoform-selectivity-drug-design/99460
• 关键词: Dissecting; Isoform; Selectivity; PI3; Kinase

The PI3 kinase enzyme controls many functions in cells and in many cases contributes to the onset and progression of diseases such as cancer, thrombosis and inflammatory diseases. Compounds that block PI3 kinase activity may be useful drugs but will need to act specifically to minimize side effects. We aim to understand the way in which inhibitors block the PI3 kinase activity with the belief that this information will allow us to make better drugs.

PI3酶控制着细胞中的许多功能，在许多情况下与癌症、血栓形成和炎症性疾病等疾病的发生和发展有关。阻断PI3激酶活性的化合物可能是有用的药物，但需要专门采取行动，将副作用降至最低。我们的目标是了解抑制剂阻止PI3激酶活性的方式，相信这些信息将使我们能够制造更好的药物。